ইকুয়েডর - স্পেনীয় - Agencia Nacional de Regulación, Control y Vigilancia Sanitaria

biosimilar collaborations ireland limited [ie] ireland - adalimumab 40 mg/0.8 ml - solucion para inyeccion - cada jeringa precargada (0.8 ml) / cada pluma precargada (0.8 ml), contiene: adalimumab 40,00 mg

ইকুয়েডর - স্পেনীয় - Agencia Nacional de Regulación, Control y Vigilancia Sanitaria

ifa/pt: cadila healthcare ltd india - adalimumab 40mg/0.8ml - solucion - cada jeringa prellenada contiene una dosis: adalimumab 40mg/0.8ml

ইকুয়েডর - স্পেনীয় - Agencia Nacional de Regulación, Control y Vigilancia Sanitaria

fresenius kabi deutschland gmbh alemania - adalimumab 40 mg - solucion inyectable - cada 0.8 ml contiene: adalimumab 40 mg

ইকুয়েডর - স্পেনীয় - Agencia Nacional de Regulación, Control y Vigilancia Sanitaria

alvotech swiss ag suiza - adalimumab 40 mg/0,4 ml - solucion inyectable - cada 0,4 ml de solución inyectable contiene: adalimumab 40 mg

পিরু - স্পেনীয় - DIGEMID (Dirección General de Medicamentos, Insumos y Drogas)

h reps s.a.c. - droguerÍa - adalimumab - solucion inyectable - 40mg/0.8ml - por jeringa precargada 0.80 ml - - agentes inmunosupresores selectivos

ইউরোপীয় ইউনিয়ন - স্পেনীয় - EMA (European Medicines Agency)

janssen-cilag international nv - guselkumab - psoriasis - inmunosupresores - plaque psoriasis tremfya is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. psoriatic arthritis tremfya, alone or in combination with methotrexate (mtx), is indicated for the treatment of active psoriatic arthritis in adult patients who have had an inadequate response or who have been intolerant to a prior disease-modifying antirheumatic drug (dmard) therapy (see section 5.

ইউরোপীয় ইউনিয়ন - স্পেনীয় - EMA (European Medicines Agency)

ucb pharma s.a.   - bimekizumab - psoriasis - inmunosupresores - plaque psoriasisbimzelx is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. psoriatic arthritisbimzelx, alone or in combination with methotrexate, is indicated for the treatment of active psoriatic arthritis in adults who have had an inadequate response or who have been intolerant to one or more disease-modifying antirheumatic drugs (dmards). axial spondyloarthritisnon-radiographic axial spondyloarthritis (nr-axspa)bimzelx is indicated for the treatment of adults with active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated c-reactive protein (crp) and/or magnetic resonance imaging (mri) who have responded inadequately or are intolerant to non-steroidal anti-inflammatory drugs (nsaids). ankylosing spondylitis (as, radiographic axial spondyloarthritis)bimzelx is indicated for the treatment of adults with active ankylosing spondylitis who have responded inadequately or are intolerant to conventional therapy.

ইউরোপীয় ইউনিয়ন - স্পেনীয় - EMA (European Medicines Agency)

hansa biopharma ab - imlifidase - desensitization, immunologic; kidney transplantation - inmunosupresores - idefirix is indicated for desensitisation treatment of highly sensitised adult kidney transplant patients with positive crossmatch against an available deceased donor. the use of idefirix should be reserved for patients unlikely to be transplanted under the available kidney allocation system including prioritisation programmes for highly sensitised patients.

উরুগোয়ে - স্পেনীয় - Ministerio de Salud (Dirección Oficina Central)

abbvie - solución inyectable - adalimumab 40 mg/0,8 ml inyectable

উরুগোয়ে - স্পেনীয় - Ministerio de Salud (Dirección Oficina Central)

abbvie - solución inyectable - adalimumab 40 mg/0,4 ml inyectable